http://rdf.ncbi.nlm.nih.gov/pubchem/reference/17636884

Outgoing Links

Predicate Object
contentType Journal Article
endingPage 3105
issn 2218-6751
2226-4477
issueIdentifier 7
pageRange 3093-3105
publicationName Translational Lung Cancer Research
startingPage 3093
bibliographicCitation Brueckl WM, Reck M, Rittmeyer A, Kollmeier J, Wesseler C, Wiest GH, Christopoulos P, Stenzinger A, Tufman A, Hoffknecht P, Ulm B, Reich F, Ficker JH, Laack E. Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV. Transl Lung Cancer Res. 2021 Jul;10(7):3093–105. PMID: 34430350; PMCID: PMC8350088.
creator http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_899cd5ceb0564c73a3a97b7bf2a46512
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e85b6727519d1b8a8393c834bc69301a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_b87e6309d80689a9ee20db990839001f
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ead0b41844d979581b00078d52575b10
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d861514468fedba5fc2b2c1bc8aee7db
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_de30770fdf54d42bfba135bdbef61bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_dad82410c502787790d89381de123bb6
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5a844148abe1cb203b24af65901f3514
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1757e02bd569c511c596b1e98e241cc4
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_d087791dae5bc87348869040a986d47a
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_5616f05a51b3fafe4299b411de7ea345
http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-7966-8980
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_a945a5f7e65f8cc35e29e60e18dbd3a2
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_c1115ca06a584ce4de2525436c23d9af
http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_05c44238d1bc42a8b582b592c2a06440
date 202107
identifier https://pubmed.ncbi.nlm.nih.gov/PMC8350088
https://doi.org/10.21037/tlcr-21-197
https://pubmed.ncbi.nlm.nih.gov/34430350
isPartOf https://portal.issn.org/resource/ISSN/2226-4477
http://rdf.ncbi.nlm.nih.gov/pubchem/journal/43494
https://portal.issn.org/resource/ISSN/2218-6751
language English
source https://pubmed.ncbi.nlm.nih.gov/
https://www.crossref.org/
title Efficacy of docetaxel plus ramucirumab as palliative second-line therapy following first-line chemotherapy plus immune-checkpoint-inhibitor combination treatment in patients with non-small cell lung cancer (NSCLC) UICC stage IV
discussesAsDerivedByTextMining http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID7168
http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_cad62314330b0a7a106aec2b9b6d9411
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11431
http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8603
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID148124
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID108157

Showing number of triples: 1 to 42 of 42.